Ticovac Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Ticovac market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to factors such as increased awareness, more travel to endemic regions, rising veterinary concerns, the growing geriatric population, and an increase in military and defense vaccinations.

Growth during the market's forecast period can be attributed to the rise in outdoor workers, increased healthcare spending, a stronger focus on regional disease control, expanded health insurance coverage, and a growing number of tick-borne encephalitis (TBE) cases. Key trends for the forecast period include advancements in vaccine production technology, the introduction of new TBE vaccines, collaborations between governments and pharmaceutical companies, progress in genetic research, and improvements in monitoring and post-vaccination care.

The rising prevalence of tick-borne diseases is expected to drive the growth of the ticovac market. Tick-borne diseases, which are transmitted through tick bites and caused by bacteria, viruses, or parasites, are increasing due to climate change, expanding tick habitats, greater human exposure, and improved diagnostic methods. Ticovac plays a crucial role in combating these diseases by providing active immunization against tick-borne encephalitis (TBE), a potentially severe viral infection. For example, in February 2024, the Centers for Disease Control and Prevention reported that the incidence of Lyme disease in the U.S. had risen by 68.8% compared to previous years, highlighting the growing burden of tick-borne diseases. This rise in incidence is expected to boost the demand for vaccines such as ticovac, driving market growth.

The increasing research and development (R&D) activities are key factor propelling the ticovac market. R&D efforts are aimed at creating new products, enhancing existing ones, and developing technologies to address emerging global health challenges. The focus on R&D in the pharmaceutical sector has led to innovations that improve vaccine formulations, including better efficacy and the ability to address emerging strains of tick-borne encephalitis. For example, in July 2024, the Department of Health and Social Care reported that the UK's pharmaceutical R&D sector spent $11.3 billion on research in 2022, emphasizing the increasing investment in R&D to address health threats like tick-borne diseases.

A significant trend in the ticovac market is the development of innovative vaccine formulations, such as suspension liquids, which offer a competitive edge. Suspension liquid vaccines are designed for intramuscular injection and are available in different dosages for both adults and children. In September 2024, Pfizer launched Ticovac in Japan, marking the first vaccine of its kind in the country for the prevention of tick-borne encephalitis. This new formulation is expected to enhance the vaccine's accessibility and effectiveness, further driving market growth.

Key player operating in the ticovac market is Pfizer Inc.

Europe was the largest region in the ticovac market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ticovac market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

TicoVac is a vaccine designed to protect against tick-borne encephalitis (TBE), a viral disease primarily transmitted through tick bites or, less frequently, through the consumption of unpasteurized dairy products from infected animals. TBE impacts the central nervous system and can cause severe neurological issues, such as meningitis and encephalitis. TicoVac works by stimulating the immune system to recognize and combat the tick-borne encephalitis virus (TBEV) if the body is exposed to it in the future.

The primary types of ticoVac formulations are inactivated vaccines and live attenuated vaccines. Tick-borne encephalitis is a viral infection transmitted by infected ticks that affects the central nervous system, potentially causing severe neurological complications. The vaccine is also used for preventing Japanese encephalitis and rabies encephalitis and is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The ticovac market research report is one of a series of new reports that provides ticovac market statistics, including ticovac industry global market size, regional shares, competitors with a ticovac market share, detailed ticovac market segments, market trends and opportunities, and any further data you may need to thrive in the ticovac industry. This ticovac market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ticovac market consists of sales of pediatric vaccines, cardiovascular and metabolic products, anti-infective medications and rare disease medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.